BILIARY TRACT CANCER

This phase II trial tests whether a combination of durvalumab (an immunotherapy), chemotherapy (GEMOX or GC), followed by lenvatinib (a targeted therapy) can prevent biliary tract cancer from coming back after surgery. About 222 adults with bile duct or gallbladder cancer will be…

This study is testing a new biologic drug called sacituzumab tirumotecan (MK-2870), alone or with chemotherapy, in people with advanced colorectal, pancreatic, or biliary tract cancers that cannot be removed by surgery. The main goals are to check safety and see if tumors shrink.…

This early-stage study tests a new drug called MK-4884 in about 120 people with advanced or metastatic solid tumors (colorectal, kidney, lung, or bile duct cancer). The main goal is to check the drug's safety and find the right dose. Researchers will monitor side effects and how …

This study is testing a drug called patritumab deruxtecan in people with advanced gastrointestinal cancers that have spread. The drug is given through a vein and aims to shrink tumors. The trial will check how safe the drug is and how many people's cancers respond to treatment. A…

This study tests a new drug called CR-001 in adults with advanced solid tumors that have spread. The goal is to find the safest dose and see if it can shrink tumors. About 290 people will take part in this early-phase trial.

This phase II trial is testing a combination of three drugs—trastuzumab rezetecan, adebrelimab, and lenvatinib—as a first treatment for people with advanced or metastatic biliary tract cancer that has HER2 markers. The study aims to see how well the drugs shrink tumors and contro…

This study tests a new combination of an immunotherapy drug (adebrelimab) plus two chemotherapy drugs (gemcitabine and nab-paclitaxel) as a first treatment for people with biliary tract cancer that cannot be removed by surgery. The goal is to see if this combo can shrink tumors a…

This study tests an experimental oral drug called S241656 (BDTX-4933) in people with advanced solid tumors that have certain genetic changes (KRAS, BRAF, or other RAS/MAPK mutations). The trial has two parts: first, finding a safe dose, then testing how well it works alone or wit…

This global Phase 3 trial is testing whether adding the experimental immunotherapy rilvegostomig to standard chemotherapy helps people with advanced biliary tract cancer live longer, compared to adding the approved drug durvalumab. About 1,100 participants with inoperable or meta…

This phase 2 trial is testing a drug called datopotamab deruxtecan (Dato-DXd), alone or with other cancer medicines, in people with advanced or metastatic solid tumours. The study includes seven cancer types and aims to see if the drug shrinks tumours and how safe it is. Around 4…

This study tests a new drug called AZD4360 in adults with advanced solid tumours that have a specific marker (CLDN18.2). The drug is an antibody-drug conjugate designed to deliver a toxic payload directly to cancer cells. The trial aims to find the safest dose and see if it shrin…

This study tests an experimental drug called YH32364 in adults with advanced solid tumors that have high levels of EGFR and have not responded to previous treatments. The trial has two parts: first, finding a safe dose in about 30 people, then testing that dose in 50 people with …

This study tests a new therapy called EB-HC01, which uses specially engineered natural killer (NK) immune cells to attack cancer cells that have two specific markers (HER2 and CEACAM5). The trial enrolls adults with advanced bile duct or gallbladder cancers that have worsened aft…

This study tests whether a new drug combination (trastuzumab deruxtecan plus rilvegostomig) works better than standard chemotherapy for people with advanced bile duct cancer that has a specific protein called HER2. About 620 adults with untreated, advanced HER2-positive bile duct…

This early-phase trial is testing a combination of three treatments for people with advanced biliary tract cancer that cannot be surgically removed. The approach delivers chemotherapy directly to the liver, along with an immunotherapy drug and a targeted therapy pill. The study a…

This Phase 2 trial tests an oral drug called BAY 2927088 (sevabertinib) in about 111 adults with advanced solid tumors that have HER2 gene mutations. The drug aims to block the abnormal HER2 protein and stop cancer growth. Participants take a 20 mg tablet daily in 3-week cycles u…

This study tests an experimental drug called LBL-024 combined with standard chemotherapy (cisplatin, gemcitabine) and bevacizumab in 140 people with advanced solid tumors. The goal is to see if the combination can shrink tumors and control the disease. Participants must be 18–75,…

This early-phase trial tests a new cell therapy called UCLH80-1 in 36 people with advanced solid tumors (colorectal, gastric, pancreatic, and bile duct cancers) that have not responded to standard treatments. The therapy uses specially engineered immune cells to target a protein …

This study tests a new drug called ivonescimab against standard chemotherapy (FOLFOX) for people with advanced bile duct cancer that has worsened after initial treatment. About 72 participants who were in the SAFIR-ABC10 trial will be randomly assigned to receive either ivonescim…

This study tests whether adding the drug zanidatamab to standard chemotherapy (with or without an immunotherapy) can help people with advanced HER2-positive bile duct cancer live longer without their cancer growing. About 286 adults with inoperable or metastatic bile duct cancer …

This early-phase study tests a new drug called IBI343 in people with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. About 470 participants will take part in mul…

This study tests a new drug called MDX2001 in people with advanced solid tumors that have spread. The main goals are to check the drug's safety and see if it can shrink tumors. About 285 adults with various cancers like lung, breast, or colon cancer will take part. This is an ear…

This study tests a new way to treat bile duct cancer that cannot be removed by surgery. It combines chemotherapy given directly into the liver with standard IV chemo, plus two additional drugs (adebrelimab and apatinib) that boost the immune system and block tumor growth. The tri…

This early-phase study tests a new drug called BL-M05D1 in people with advanced or metastatic solid tumors (like stomach, pancreatic, or bile duct cancer) that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug c…

This early-phase study tests a new drug called IMC-002 in about 62 adults with advanced solid tumors that no longer respond to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can help control the cancer. Participants receive t…

This phase 2 trial is testing several new immunotherapy drugs, alone or combined with standard chemotherapy, in people with advanced liver or bile duct cancer. The goal is to see if these combinations can shrink tumors or slow the disease. About 294 adults whose cancer has spread…

This phase IIa trial is testing two experimental drugs, HX009 and IN10018, given together with or without standard chemotherapy, in 124 adults with advanced solid tumors, specifically biliary tract cancer and melanoma. The study aims to find the best dose and see if the combinati…

This study tests an experimental drug called TQB2102 in people with advanced bile duct cancer that has a specific marker (HER2-positive). The goal is to see if the drug can shrink tumors or slow the cancer's growth. About 102 adults aged 18 to 75 with good organ function are bein…

This early-phase trial is testing a new antibody drug called ZM008, first by itself and then together with another drug (toripalimab), in people with advanced solid tumors like lung, head and neck, and pancreatic cancers. The study aims to find a safe dose and see if the combinat…

This study tests a genetically modified herpes virus (RP2) that infects and destroys cancer cells while also stimulating the immune system. It is given alone or together with standard drugs (bevacizumab, atezolizumab, or durvalumab) to 60 adults with advanced liver or bile duct c…

This study tests a combination of three drugs (trastuzumab, serplulimab, and chemotherapy) in 20 adults with advanced bile duct or bladder cancers that have stopped responding to standard treatments. The goal is to see if this approach can shrink tumors and improve survival. Part…

This study tests an experimental drug called SHR-A1904 in people with advanced biliary tract cancer (bile duct cancer) that has not responded to previous treatments. The drug targets a protein called CLDN18.2 found on some cancer cells. The trial aims to see if the drug can shrin…

This Phase 1 trial tests a new drug called BL-M07D1 in 280 adults with advanced HER2-positive cancers, including breast, lung, and stomach cancers. The study aims to find safe doses and check for early signs of tumor shrinkage. Participants must have tried at least two prior trea…

This study tests two experimental drugs, AK130 and AK112, in people with advanced biliary tract cancer (a type of bile duct cancer). The first part finds a safe dose; the second part checks if the combination shrinks tumors. About 135 participants will take part.

This phase 2 trial is testing whether a combination of two immune-boosting drugs, ligufalimab and cadonilimab, can shrink advanced liver or bile duct cancers that have stopped responding to prior treatments. About 64 adults will receive the drugs by IV every three weeks. The main…

This study looks at the safety of the drug Tasfygo in 60 people with advanced biliary tract cancer that has a specific gene change (FGFR2 fusion) and has gotten worse after chemotherapy. Researchers will track side effects and how well the drug works. The goal is to make sure the…

This phase II trial is testing a combination of two chemotherapy drugs—trifluridine/tipiracil (pills) and oxaliplatin (IV)—in people with advanced or metastatic biliary tract cancer whose first treatment stopped working. The goal is to see if this combo can control the cancer bet…

This study tests a new drug called AZD0901, alone or with other cancer treatments, in people with advanced solid tumors that have a specific protein called CLDN18.2. The goal is to see if the drug is safe and can shrink tumors. About 224 adults with stomach, pancreatic, or bile d…

This study tests a precision medicine approach for people with advanced biliary tract cancer that has a specific IDH1 gene mutation and has stopped responding to standard chemotherapy. About 300 participants will receive a combination of ivosidenib (a targeted pill) plus either l…

This early-phase study tests a new drug, LNCB74, in people with advanced solid tumors (ovarian, breast, endometrial, bile duct, or lung cancer) that have not responded to standard treatments. The drug is designed to deliver a cancer-killing agent directly to tumor cells. The main…

This early-phase trial tests a new drug called MT-4561 in about 27 people with advanced solid tumors (like lung, breast, or pancreatic cancer) who have no standard options left. The main goals are to find a safe dose and see if the drug can shrink tumors. It is a first-in-human s…

This early-phase study tests whether adding heat therapy and a special type of radiation to standard chemoimmunotherapy is safe and feasible for people with advanced bile duct cancer that cannot be removed by surgery. About 15 participants will receive the combination treatment. …

This phase 2 trial is testing whether adding two immunotherapy drugs (tuvonralimab and iparomlimab) to standard chemotherapy before surgery can improve outcomes for people with bile duct or gallbladder cancer. About 45 adults with resectable or borderline-resectable cancer will r…

This study is testing whether a quick lab test called MiniPDX can help doctors choose the best chemotherapy drugs for people with bile duct cancer after surgery. The test measures how sensitive a patient's tumor cells are to different drugs in just 7 days. Researchers will follow…

This study compares two types of nerve blocks—coeliac plexus block and splanchnic nerve block—to see which one reduces pain better in adults with upper abdominal cancer. Forty-four participants will receive one of the procedures and be monitored for pain, opioid use, and quality …

This early-stage trial tests a new drug called GB18 in 18-36 cancer patients who are losing weight and appetite due to their illness (cachexia). The drug is given as a shot under the skin. The main goal is to check safety, but researchers will also see if it helps patients gain w…

This study tests whether using virtual reality (VR) can reduce severe belly pain and improve quality of life in people with digestive tract cancers. 360 participants will be split into three groups: one using a skills-based VR program, one using distracting VR videos, and a contr…

This study compares three routine pain control methods used during minimally invasive cancer surgery: a nerve block plus local anesthetic, nerve block alone, or local anesthetic alone. About 48 adults having surgery for various cancers will be randomly assigned to one of the thre…

This study explores whether a blood test that detects circulating tumor DNA (ctDNA) can help doctors personalize treatment for people with five types of advanced cancer: non-small cell lung cancer, gastrointestinal stromal tumors, colorectal cancer, biliary tract cancer, and ovar…

This study looks at tumor samples from 2,100 Chinese patients with lung, gynecologic, bile duct, or bladder cancers. Researchers will compare different HER2 testing methods to see how well they agree with each other. The goal is to improve the accuracy of HER2 testing, which help…

This study is testing whether a blood test that looks for tumor DNA (ctDNA) can be as good as a tissue biopsy for finding genetic changes in advanced bile duct cancer. Researchers will enroll 200 adults with advanced biliary tract cancer across multiple hospitals in Korea. The go…

This study enrolls 100 adults with advanced biliary tract cancer who are already scheduled to receive a combination of two drugs (lenvatinib and pembrolizumab). Researchers will collect blood and tumor samples to look for genetic markers that might predict who responds best to tr…

This study is testing whether a blood test that looks for tumor DNA (ctDNA) can find genetic changes in advanced bile duct cancer as well as a traditional tissue biopsy. The goal is to make it easier and less invasive to identify which patients might benefit from targeted therapi…

This study aims to find out if certain Helicobacter bacteria (like H. pylori) are more common in people with biliary tract cancer than in those with non-cancerous gallbladder issues. Researchers will test tissue samples from 250 participants, including cancer patients, people wit…

This study collects and stores tissue and blood samples from people with stomach, esophageal, pancreatic, liver, and other gastrointestinal cancers. The goal is to build a large database of samples and medical information to help researchers understand these cancers better. Parti…

This study is testing whether measuring ctDNA (bits of tumor DNA) in blood or stool can help doctors manage patients with cancers of the digestive tract, including pancreas, colon, and bile duct cancers. Researchers will track survival and see how these markers relate to outcomes…